Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice.

Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, Azhar S.

J Lipid Res. 2010 Jun;51(6):1496-503. doi: 10.1194/jlr.M003665. Epub 2010 Jan 14.

2.

L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation.

Buga GM, Navab M, Imaizumi S, Reddy ST, Yekta B, Hough G, Chanslor S, Anantharamaiah GM, Fogelman AM.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):283-9. doi: 10.1161/ATVBAHA.109.200162. Epub 2009 Dec 3. Erratum in: Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):e174. Dosage error in article text.

3.

The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Tabet F, Remaley AT, Segaliny AI, Millet J, Yan L, Nakhla S, Barter PJ, Rye KA, Lambert G.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):246-52. doi: 10.1161/ATVBAHA.109.200196. Epub 2009 Dec 3.

4.

Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Barter P.

Am J Cardiol. 2009 Nov 16;104(10 Suppl):10E-5E. doi: 10.1016/j.amjcard.2009.09.014.

PMID:
19895939
5.

Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses.

Yvan-Charvet L, Wang N, Tall AR.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):139-43. doi: 10.1161/ATVBAHA.108.179283. Epub 2009 Oct 1. Review.

6.

An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide.

Wool GD, Vaisar T, Reardon CA, Getz GS.

J Lipid Res. 2009 Sep;50(9):1889-900. doi: 10.1194/jlr.M900151-JLR200. Epub 2009 May 11.

7.

HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Remaley AT, Amar M, Sviridov D.

Expert Rev Cardiovasc Ther. 2008 Oct;6(9):1203-15. doi: 10.1586/14779072.6.9.1203. Review.

8.

Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux.

Sankaranarayanan S, Oram JF, Asztalos BF, Vaughan AM, Lund-Katz S, Adorni MP, Phillips MC, Rothblat GH.

J Lipid Res. 2009 Feb;50(2):275-84. doi: 10.1194/jlr.M800362-JLR200. Epub 2008 Sep 30.

9.

Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides.

Sethi AA, Stonik JA, Thomas F, Demosky SJ, Amar M, Neufeld E, Brewer HB, Davidson WS, D'Souza W, Sviridov D, Remaley AT.

J Biol Chem. 2008 Nov 21;283(47):32273-82. doi: 10.1074/jbc.M804461200. Epub 2008 Sep 19.

10.

Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes.

Silva RA, Huang R, Morris J, Fang J, Gracheva EO, Ren G, Kontush A, Jerome WG, Rye KA, Davidson WS.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12176-81. doi: 10.1073/pnas.0803626105. Epub 2008 Aug 21.

11.

Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo.

Mukhamedova N, Escher G, D'Souza W, Tchoua U, Grant A, Krozowski Z, Bukrinsky M, Sviridov D.

J Lipid Res. 2008 Nov;49(11):2312-22. doi: 10.1194/jlr.M800095-JLR200. Epub 2008 Jul 12.

12.

Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.

Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, Fogelman AM.

J Lipid Res. 2008 Nov;49(11):2302-11. doi: 10.1194/jlr.M800075-JLR200. Epub 2008 Jul 11. Erratum in: J Lipid Res. 2008 Dec;49(12):2698.

13.

High-density lipoprotein reduces the human monocyte inflammatory response.

Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, Remaley AT, Sviridov D, Chin-Dusting J.

Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2071-7. doi: 10.1161/ATVBAHA.108.168690. Epub 2008 Jul 10.

14.

Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

deGoma EM, deGoma RL, Rader DJ.

J Am Coll Cardiol. 2008 Jun 10;51(23):2199-211. doi: 10.1016/j.jacc.2008.03.016. Review.

15.

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients.

Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, Movva R, Navab M, Fogelman AM, Rader DJ.

J Lipid Res. 2008 Jun;49(6):1344-52. doi: 10.1194/jlr.P800003-JLR200. Epub 2008 Mar 6.

16.

Pharmacological therapies for raising HDL cholesterol beyond synthetic small molecules.

Garcia RA.

Curr Opin Investig Drugs. 2008 Mar;9(3):274-80. Review.

PMID:
18311663
17.

Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I.

Duong PT, Weibel GL, Lund-Katz S, Rothblat GH, Phillips MC.

J Lipid Res. 2008 May;49(5):1006-14. doi: 10.1194/jlr.M700506-JLR200. Epub 2008 Feb 5.

18.

The role of different regions of ATP-binding cassette transporter A1 in cholesterol efflux.

Mukhamedova N, Fu Y, Bukrinsky M, Remaley AT, Sviridov D.

Biochemistry. 2007 Aug 21;46(33):9388-98. Epub 2007 Jul 26.

PMID:
17655203
19.

Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis.

Sethi AA, Amar M, Shamburek RD, Remaley AT.

Curr Opin Investig Drugs. 2007 Mar;8(3):201-12. Review.

PMID:
17408115
20.

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators.

JAMA. 2007 Apr 18;297(15):1675-82. Epub 2007 Mar 26.

PMID:
17387133

Supplemental Content

Support Center